Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shattuck Labs, Inc.STTK · Entity 5224 | See Remarks | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shattuck Labs, Inc.
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,366 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 12,805 · Balance 93,366 |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 | Direct | 0 |
Reported balance
After 2026-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-15 · Exercise / conversion · Disposed 12,805 · Balance 0 F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 18, 2026 07:46 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionWarrants (Right to Buy) · Derivative | 12,805 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-26-227910 · ownership.xml · derivative · entry 2 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| May 15, 2026 Filed May 18, 2026 07:46 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 12,805 | $1.08 | $13,888.30 |
DisclosureSEC source: 0001193125-26-227910 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,366 Read SEC document |
| May 10, 2026 Filed May 12, 2026 21:36 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 968 | $6.85 | $6,630.80 |
DisclosureSEC source: 0001193125-26-219935 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,561 Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 21:11 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 593 | $4.15 | $2,460.95 |
DisclosureSEC source: 0001193125-26-024424 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,529 Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:55 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 351,400 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-011860 · ownership.xml · derivative · entry 2 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,400 Underlying: Common Stock · 351,400 shares Expires 2036-01-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 351,400 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:55 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 4,153 | $4.75 | $19,726.75 |
DisclosureSEC source: 0001193125-26-011860 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,122 Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantWarrants (Right to Buy) · Derivative | 12,805 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-25-189086 · ownership.xml · derivative · entry 2 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,805 Underlying: Common Stock · 12,805 shares Expires not disclosed F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 12,805 | $0.87 | $11,110.90 |
DisclosureSEC source: 0001193125-25-189086 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,275 F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 23:02 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 177,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000950170-25-010001 · ownership.xml · derivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 177,000 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:02 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 967 | $10.42 | $10,076.14 |
DisclosureSEC source: 0000950170-24-059492 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,470 Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,459 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · derivative · entry 7 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,391 Underlying: Common Stock · 6,459 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 25, 2023, one-quarter of which vested on January 10, 2024 and the remaining three-quarters of which will vest in approximately equal monthly installments through January 10, 2027. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,650 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · derivative · entry 6 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 4,650 shares Expires 2032-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option was granted to the Reporting Person on September 8, 2022, one-third of which vested on September 8, 2023 and the remaining two-thirds of which will vest on September 8, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 4,895 | $10.53 | $51,544.35 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · nonDerivative · entry 5 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,437 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 6,459 | $10.53 | $68,013.27 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · nonDerivative · entry 4 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,332 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 6,459 | $3.57 | $23,058.63 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · nonDerivative · entry 3 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 4,650 | $10.53 | $48,964.50 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · nonDerivative · entry 2 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,332 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 4,650 | $3.51 | $16,321.50 |
DisclosureSEC source: 0000950170-24-028811 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 593 | $9.99 | $5,924.07 |
DisclosureSEC source: 0000950170-24-009381 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,332 Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 98,100 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-24-004665 · ownership.xml · derivative · entry 2 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,100 Underlying: Common Stock · 98,100 shares Expires 2034-01-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 98,100 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 49,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-004665 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,925 F1 · shares: Consists of 49,050 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:11 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 31,800 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0000950170-23-021768 · ownership.xml · derivative · entry 2 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,800 Underlying: Common Stock · 31,800 shares Expires 2033-05-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 31,800 shares of the Issuer's common stock, one quarter of which will vest on May 10, 2024, with the remaining three quarters vesting in equal monthly installments through May 10, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:11 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 15,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-021768 · ownership.xml · nonDerivative · entry 1 Stout Stephen · CIK 0001970664 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,875 F1 · shares: Consists of 15,900 restricted stock units, which will vest in four equal annual installments beginning on May 10, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.